Highmark Commercial Medical Policy - Pennsylvania |
Medical Policy: | G-44-001 |
Topic: | Extracorporeal Membrane Oxygenation (ECMO) for Adult Conditions |
Section: | Miscellaneous |
Effective Date: | July 2, 2018 |
Issue Date: | July 2, 2018 |
Last Reviewed: | February 2018 |
Extracorporeal membrane oxygenation (ECMO) provides extracorporeal circulation and physiologic gas exchange for temporary cardiorespiratory support in cases of severe respiratory and cardiorespiratory failure. ECMO is used in clinical situations in which there is respiratory or cardiac failure in which death would be imminent unless medical interventions can immediately reverse the underlying disease process, or physiologic functions can be supported for long enough that normal reparative processes or treatment can occur (e.g., resolution of acute respiratory distress syndrome, treatment of infection) or other life-saving intervention can be delivered (e.g. provision of a lung transplant). Potential indications for ECMO in adults include acute, potentially reversible respiratory failure due to a variety of causes; as a bridge to lung transplant; in potentially reversible cardiogenic shock; and as an adjunct to cardiopulmonary resuscitation (ECMO-assisted cardiopulmonary resuscitation [ECPR]). |
This policy is designed to address medical guidelines that are appropriate for the majority of individuals with a particular disease, illness, or condition. Each person's unique clinical circumstances may warrant individual consideration, based on review of applicable medical records.
Policy Position Coverage is subject to the specific terms of the member’s benefit plan. |
The use of ECMO in adults may be considered medically necessary for the management of acute respiratory failure when ALL of the following criteria are met:
*Oxygenation Index = FIO2 x 100 x MAP/PaO2 mm Hg (where FIO2 x 100 = FIO2 as percentage; MAP = mean airway pressure in cm H2O; PaO2 = partial pressure of oxygen in arterial blood).
AND
NONE of the following contraindications is present:
**Assessment of ECMO futility:
Patients undergoing ECMO treatment should be periodically reassessed for clinical improvement. ECMO should not be continued indefinitely if the ANY of the following criteria are met:
The use of ECMO in adults may be considered medically necessary as a bridge to heart, lung, or combined heart-lung transplantation for the management of respiratory, cardiac, or combined cardiorespiratory failure refractory to optimal conventional therapy.
The use of ECMO in adults is considered experimental/investigational when the above criteria are not met, including but not limited to acute and refractory cardiogenic shock and as an adjunct to cardiopulmonary resuscitation.
SEE table attachment for more information. |
Place of Service: Inpatient |
Experimental/Investigational (E/I) services are not covered regardless of place of service.
The policy position applies to all commercial lines of business |
Denial Statements |
Services that do not meet the criteria of this policy will be considered experimental/investigational (E/I). A network provider can bill the member for the experimental/investigational service. The provider must give advance written notice informing the member that the service has been deemed E/I. The member must be provided with an estimate of the cost and the member must agree in writing to assume financial responsibility in advance of receiving the service. The signed agreement must be maintained in the provider’s records.
Links |
04/2018: Coverage Criteria Established for Extracorporeal Membrane Oxygenation (ECMO) for Adult Conditions